The resulting formulations, IL3-Exo-Imatinib and IL3-Exo-BCR-ABL siRNA demonstrated specific targeting ability against CML cells and effectively inhibited cancer cell growth both in vitro and in vivo [227]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.